Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Drug Expenditure Higher than Apparent Due to Hidden Drug Expenditure: Korosho
October 12, 2011
- Headquarters for Promotion of Social Security Reform Holds 1st Meeting
October 11, 2011
- Korosho Expresses Opposition to Break-Up, Privatization of PMDA
October 11, 2011
- Korosho Asks Committee to Discuss Re-pricing of Combination Drugs with Long-listed APIs
October 10, 2011
- Chuikyo to Focus on NHI Price Reduction for Long-listed Drugs: Dr Adachi
October 10, 2011
- PFSB’s Safety Division Calls For Revision of Tegretol Package Insert
October 10, 2011
- Korosho Announces Revision of Precautions in Prazaxa Package Insert
October 10, 2011
- Decline in Research by Univ. Hospital Doctors Presents “Alarming Situation”: MEXT Official
October 10, 2011
- HPV Vaccines Competing for Public Subsidies; Are Parents Avoiding Vaccination by OB/GYN Doctors?
October 10, 2011
- MHLW to Set Up New System to Support Ultra-Orphan Drug Development
October 7, 2011
- Number of Pharmacies Qualifying for Premiums for GE Drug Dispensing Systems Down in 2010
October 6, 2011
- MHLW Issues GL for Clinical Evaluation for Renal Anemia Drugs
October 5, 2011
- PMDA Invites Opinions on Candidate Drugs for JP Listing
October 5, 2011
- MHLW to Adopt Self-Evaluation by Generic Drug Makers for Stable Supply
October 5, 2011
- Korosho to Support Pharmacies’ Participation in Home Healthcare
October 5, 2011
- FPMAJ States Difficulty in Identifying Anticancer Drugs in Terms of Adverse Reactions
October 4, 2011
- MHLW Intends to Improve Self-sufficiency Ratio in HBIG Preparation
October 4, 2011
- Partial Change in Approval Is Not Necessary for 14 Products Including Allegra: PFSB
October 4, 2011
- Bill for Healthcare Reform for Elderly to Be Submitted to 2012 Diet: Health Minister
October 4, 2011
- METI Budget Request Includes ¥3.3 Bil. to Promote “Healthcare Industry Creation”
October 3, 2011
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…